The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

In a modelling study, Dr. Allison Portnoy and colleagues explore the cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries.

Related Keywords

United Kingdom ,United States ,Canada ,Canadian ,Meganb Murray , ,United Kingdom Research Innovation Economic ,Global Health Cost Consortium ,National Institutes Of Health ,World Health Organization ,Melinda Gates Foundation ,Harvard Medical School ,World Bank ,Canadian Centennial Scholarship Fund ,United Kingdom Research Innovation Medical Council ,Countries Clinical Trials Partnership ,Wellcome ,Research Council ,Creative Commons Attribution ,United Kingdom Research ,Innovation Medical Research Council ,Wellcome Trust ,National Institutes ,Developing Countries Clinical Trials Partnership ,Innovation Economic ,Social Research Council ,Coronavirus Disease ,Full Value ,Vaccines Assessment ,Product Characteristics ,New Tuberculosis Vaccines ,Global Burden ,Hiv Vaccines ,Tuberculosis ,Vaccines ,Vaccination And Immunization ,Low And Middle Income Countries ,Vaccine Development ,Cost Effectiveness Analysis ,Economic Analysis ,